Morgan Stanley’s Bionano Genomics BNGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08K Sell
927
-1,297
-58% -$1.66K ﹤0.01% 7422
2025
Q4
$3.4K Sell
2,224
-3,984
-64% -$6.89K ﹤0.01% 7137
2025
Q3
$10.6K Sell
6,208
-5,447
-47% -$17.3K ﹤0.01% 6881
2025
Q2
$38.2K Sell
11,655
-336
-3% -$1.25K ﹤0.01% 6443
2025
Q1
$33.5K Buy
11,991
+3,107
+35% +$20.3K ﹤0.01% 6406
2024
Q4
$154K Buy
8,884
+8,456
+1,976% +$145K ﹤0.01% 5879
2024
Q3
$11.7K Sell
428
-92
-18% -$2.86K ﹤0.01% 6672
2024
Q2
$21.2K Sell
520
-227
-30% -$12.5K ﹤0.01% 6439
2024
Q1
$49.8K Sell
747
-1,995
-73% -$149K ﹤0.01% 6215
2023
Q4
$311K Buy
2,742
+1,652
+152% +$173K ﹤0.01% 5783
2023
Q3
$198K Sell
1,090
-732
-40% -$192K ﹤0.01% 5578
2023
Q2
$667K Sell
1,822
-3,120
-63% -$1.41M ﹤0.01% 5068
2023
Q1
$3.29M Sell
4,942
-436
-8% -$387K ﹤0.01% 4116
2022
Q4
$4.71M Sell
5,378
-195
-3% -$245K ﹤0.01% 3808
2022
Q3
$6.12M Buy
5,573
+522
+10% +$690K ﹤0.01% 3499
2022
Q2
$4.18M Buy
5,051
+1,653
+49% +$1.7M ﹤0.01% 3919
2022
Q1
$5.26M Buy
3,398
+799
+31% +$1.08M ﹤0.01% 3632
2021
Q4
$4.66M Buy
2,599
+1,446
+125% +$3.87M ﹤0.01% 3792
2021
Q3
$3.81M Sell
1,153
-1,627
-59% -$5.69M ﹤0.01% 4001
2021
Q2
$12.2M Buy
2,780
+2,411
+653% +$9.52M ﹤0.01% 2759
2021
Q1
$1.79M Buy
369
+365
+9,125% +$2.06M ﹤0.01% 4345
2020
Q4
$8K Buy
+4
New +$1.5K ﹤0.01% 6684
2020
Q3
Sell
-1
Closed -$388 6729
2020
Q2
$0 Hold
1
﹤0.01% 6600
2020
Q1
$0 Hold
1
﹤0.01% 6569
2019
Q4
$0 Sell
1
-1
-50% -$585 ﹤0.01% 6648
2019
Q3
$1K Buy
2
+1
+100% +$1.09K ﹤0.01% 6531
2019
Q2
$1K Hold
1
﹤0.01% 6518
2019
Q1
$2K Hold
1
﹤0.01% 6441
2018
Q4
$2K Hold
1
﹤0.01% 6407
2018
Q3
$2K Buy
+1
New +$4.26K ﹤0.01% 6560

Other funds holding BNGO

Morgan Stanley's BNGO Position: Q1 2026 in Review

Morgan Stanley reduced its Bionano Genomics (BNGO) stake by 58% in Q1 2026, selling an estimated $1.66K and leaving 927 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #7422.

Morgan Stanley first reported a position in BNGO in Q3 2018 and has held it in 30 quarters since. The position peaked at $12.2M in Q2 2021. 32 funds tracked by Wall St. Rank hold BNGO as of Q1 2026.

  • Morgan Stanley held 927 shares of Bionano Genomics worth $1.08K as of Q1 2026.
  • Morgan Stanley sold 1,297 Bionano Genomics shares in Q1 2026, an estimated $1.66K.
  • Bionano Genomics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7422 holding.
  • Morgan Stanley first reported a position in Bionano Genomics in Q3 2018 and has held it in 30 quarters since.
  • Morgan Stanley's Bionano Genomics position peaked at $12.2M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.